Organon & Co (0A9W) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Organon & Co $11.95, price $13.71, upside -12.8%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
60‑month range $5.70 – $32.75 · fair‑value band $3.85 – $15.54 · the $13.71 price screens above the $11.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Show more
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Stock analysis
Organon & Co (0A9W) currently trades at $13.71, while our model-based Fair Value estimate is $11.95, 12.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $12.80 per share, and 7 of the 22 models we run sit above the $13.71 price.
Bear case: the Asset-Based group reads lowest at $1.71, and 15 of the 22 models stay below the price. Evidence for this calculation is high.
Scenario range: $3.85 (bear) to $15.54 (bull), the price of $13.71 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Organon & Co reported revenue of $6.2B in FY2025 versus $6.3B in FY2021, a compound −0.4%/yr. Reported net income was $187M in FY2025, compounding −39.0%/yr from FY2021.
Key figures
Market cap $361B · P/E ratio 0.0 · EPS (TTM) $2.88 · Dividend yield 0.6% · Net margin 3.0% · Return on equity 34.1% · Return on assets (EBIT) 13.1% · Operating margin 18.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 140% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −13%, 0A9W screens richer than that median.
Fair Value models
Bear $3.85Fair Value $11.95Bull $15.54
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($2.12 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−2.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−8.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.0%
Dividend (yield on the price)0.6%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.30% → 20%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.7% a year for the price and −1.2% for the forecasts.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Organon & Co Fair Value". https://www.fairvalue-calculator.com/stock/0A9W
Frequently asked questions
Is Organon & Co (0A9W) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of $11.95 versus a price of $13.71, about −13% upside (overvalued).
What is the fair value of 0A9W?
Our model-based fair value for Organon & Co is $11.95 (as of Sep 28, 2026), built from audited fundamentals. The current price: $13.71.
What is the quality score of 0A9W?
Organon & Co has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Organon & Co (0A9W)?
Our model-based price target is the fair value of $11.95 (as of Sep 28, 2026) from 22 valuation models. Cautious scenario $3.85, optimistic scenario $15.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Organon & Co stock forecast for 2026?
Our models put fair value at $11.95, about −13% upside versus a price of $13.71 (overvalued). Cautious scenario $3.85, optimistic scenario $15.54. The calculation is refreshed regularly with new filings.
What is the revenue of Organon & Co (0A9W)?
Organon & Co reported trailing-twelve-month revenue of about $6.2B (latest available figure, as of Sep 28, 2026).
Does Organon & Co pay a dividend?
Organon & Co currently shows a dividend yield of about 0.58% relative to its recent price (as of Sep 28, 2026).
What growth is priced into Organon & Co (0A9W)?
For today's price to be fair in a discounted-cash-flow model, Organon & Co would have to grow free cash flow by +19.5 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -0.4 % per year. As of Sep 28, 2026.
What discount rate (WACC) does the fair value of 0A9W use?
Our models discount Organon & Co at 10.5 %: a base by market capitalisation (mega), damped by beta 1.54, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Organon & Co that is +19.5 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Organon & Co (0A9W) delivered so far?
Over the past 4 years revenue at Organon & Co grew -0.4 % a year. The price currently implies +19.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of Organon & Co (0A9W)?
The free-cash-flow yield on the price is 10.76 %: that much free cash flow Organon & Co produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Organon & Co (0A9W)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Organon & Co it is $11.95 per share (as of Sep 28, 2026), against a price of $13.71. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Organon & Co stock overvalued or undervalued in 2026?
As of Sep 28, 2026, 0A9W trades above its calculated fair value: price $13.71, fair value $11.95, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0A9W?
No. The price is what the market pays today ($13.71); the fair value is what the company's own numbers justify ($11.95). For Organon & Co the two are $1.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is Organon & Co worth?
The market values Organon & Co at about $361B (market capitalisation, as of Sep 28, 2026). Per share that is $13.71; our models calculate a fair value of $11.95 per share.
What do the bullish and bearish scenarios say about 0A9W?
Our models span a range for Organon & Co: cautious scenario $3.85, base $11.95, optimistic $15.54 per share (as of Sep 28, 2026, price $13.71). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0A9W from its 52-week high?
Organon & Co trades at $13.71, about 1% below its 52-week high of $13.78 and 140% above the low of $5.70 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $11.95 is for.
Which stocks are comparable to Organon & Co?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Organon & Co stock attractive at the current price?
The data as of Sep 28, 2026: price $13.71, calculated fair value $11.95 (−13%), Quality Score 49/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0A9W calculated?
We run Organon & Co through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $11.95, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Organon & Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Organon & Co (0A9W)?
The closing price on Oct 2, 2026 was $13.71. Our model-based fair value is $11.95, about −13% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Organon & Co right now?
The model range is unusually wide ($3.85 to $15.54). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Organon & Co
How large is the market capitalisation of Organon & Co (0A9W)?
The market capitalisation of Organon & Co is $361B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Organon & Co (0A9W)?
The price-to-earnings ratio of Organon & Co is 0.0 (as of Jul 24, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What are the earnings per share of Organon & Co (0A9W)?
Earnings per share at Organon & Co are $2.88 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Organon & Co (0A9W)?
The dividend yield of Organon & Co is 0.6% (payout 2.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Organon & Co (0A9W)?
The net margin of Organon & Co is 3.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Organon & Co (0A9W)?
The return on equity (ROE) of Organon & Co is 34.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Organon & Co (0A9W)?
On an EBIT basis the return on assets of Organon & Co is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Organon & Co (0A9W)?
The operating margin of Organon & Co is 18.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Organon & Co (0A9W)?
Revenue at Organon & Co is growing −3.5% versus a year earlier (3y avg +0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Organon & Co (0A9W)?
Earnings per share at Organon & Co are growing +66.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Organon & Co (0A9W) carry?
The net debt of Organon & Co is $8.1B (fiscal year 2025, ≈ 21.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
